Benjamin Jackson net worth and biography

Benjamin Jackson Biography and Net Worth

General Counsel of Sera Prognostics

Benjamin G. Jackson has served as our General Counsel since April 2021. From February 2006 to March 2021, Mr. Jackson was employed by Myriad Genetics, most recently serving as Executive Vice President, General Counsel and Secretary. Mr. Jackson held various positions in Myriad’s Legal Department, including serving as associate general counsel prior to assuming the role of general counsel. Mr. Jackson received his J.D. from the J. Reuben Clark Law School at Brigham Young University and a B.S. in microbiology, immunology and molecular genetics from the University of California, Los Angeles.

What is Benjamin Jackson's net worth?: The estimated net worth of Benjamin Jackson is at least $325.51 thousand as of September 10th, 2026. Mr. Jackson owns 159,566 shares of Sera Prognostics stock worth more than $325,515 as of November 1st. This net worth approximation does not reflect any other investments that Mr. Jackson may own. Learn More about Benjamin Jackson's net worth.
How do I contact Benjamin Jackson?: The corporate mailing address for Mr. Jackson and other Sera Prognostics executives is 2749 E. Parleys Way, Suite 200, Salt Lake City, UT, 84109. Sera Prognostics can also be reached via phone at 801-990-0520 and via email at [email protected]. Learn More on Benjamin Jackson's contact information.
Has Benjamin Jackson been buying or selling shares of Sera Prognostics?: Benjamin Jackson has not been actively trading shares of Sera Prognostics in the last ninety days. Most recently, Benjamin Jackson sold 2,190 shares of the business's stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $2.00, for a transaction totalling $4,380.00. Following the completion of the sale, the general counsel now directly owns 159,566 shares of the company's stock, valued at $319,132. Learn More on Benjamin Jackson's trading history.
Who are Sera Prognostics' active insiders?: Sera Prognostics' insider roster includes Austin Aerts (Strategic Advisor), John Boniface (Chief Scientific Officer), Robert Harrison (Information Advisor), Benjamin Jackson (General Counsel), Paul Kearney (Data Science Advisor), Sandra Lawrence (Director), Zhenya Lindgardt (President and CEO), Mansoor Mirza (Director), and Joshua Phillips (Director). Learn More on Sera Prognostics' active insiders.
Are insiders buying or selling shares of Sera Prognostics?: In the last twelve months, insiders at the sold shares 39 times. They sold a total of 173,136 shares worth more than $404,365.05. The most recent insider tranaction occured on October, 12th when insider Tiffany Eul Davis Inglis sold 8,024 shares worth more than $16,288.72. Insiders at Sera Prognostics own 11.3% of the company. Learn More about insider trades at Sera Prognostics.
Information on this page was last updated on 10/12/2026.

Benjamin Jackson Insider Trading History at Sera Prognostics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/10/2026	Sell	2,190	$2.00	$4,380.00	159,566
3/11/2026	Sell	1,027	$2.04	$2,095.08	114,720
3/9/2026	Sell	3,119	$1.96	$6,113.24	115,747
12/10/2025	Sell	892	$3.31	$2,952.52	118,866
9/11/2025	Sell	934	$3.13	$2,923.42	126,817
6/10/2025	Sell	965	$1.48	$1,428.20	134,198
5/8/2025	Sell	7,084	$2.44	$17,284.96	131,460
3/6/2025	Sell	2,285	$4.16	$9,505.60	138,544
1/13/2025	Sell	7,912	$6.38	$50,478.56	120,561
1/10/2025	Sell	13,272	$7.42	$98,478.24	128,473
11/11/2024	Sell	4,727	$7.32	$34,601.64	135,528
2/6/2024	Sell	5,665	$8.03	$45,489.95	152,035
12/7/2023	Sell	10,000	$5.22	$52,200.00	157,700
6/14/2022	Buy	8,000	$1.20	$9,600.00	8,000

Benjamin Jackson Buying and Selling Activity at Sera Prognostics

Sera Prognostics Company Overview

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $2.04

$2.03

$2.10

50 Day Range

MA: $2.05

$1.98

$2.18

2 Week Range

Now: $2.04

$1.56

$3.85

Volume

85,987 shs

Average Volume

14,339 shs

Market Capitalization

$80.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06